MyNgan Duong

List of Publications by Citations

12 papers	238 citations	8 h-index	12 g-index
12 ext. papers	268 ext. citations	4.6 avg, IF	2.46 L-index

#	Paper	IF	Citations
12	Relative contributions of ABCA1 and SR-BI to cholesterol efflux to serum from fibroblasts and macrophages. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2006**, 26, 541-7	9.4	89
11	Evidence that hepatic lipase and endothelial lipase have different substrate specificities for high-density lipoprotein phospholipids. *Biochemistry*, **2003**, 42, 13778-85	3.2	34
10	Regression of coronary atherosclerosis with infusions of the high-density lipoprotein mimetic CER-001 in patients with more extensive plaque burden. *Cardiovascular Diagnosis and Therapy*, **2017**, 7, 252-263	2.6	32
9	Liver ABCA1 deletion in LDLrKO mice does not impair macrophage reverse cholesterol transport or exacerbate atherogenesis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2013**, 33, 2288-96	9.4	32
8	High-density lipoproteins attenuate high glucose-impaired endothelial cell signaling and functions: potential implications for improved vascular repair in diabetes. *Cardiovascular Diabetology*, **2017**, 16, 121	8.7	13
7	CETP Inhibition in CVD Prevention: an Actual Appraisal. *Current Cardiology Reports*, **2016**, 18, 43	4.2	12
6	Induction of obesity impairs reverse cholesterol transport in ob/ob mice. *PLoS ONE*, **2018**, 13, e0202102	3.7	12
5	HDL function and subclinical atherosclerosis in juvenile idiopathic arthritis. *Cardiovascular Diagnosis and Therapy*, **2016**, 6, 34-43	2.6	9
4	Acute high-density lipoprotein therapies. *Current Opinion in Lipidology*, **2015**, 26, 521-5	4.4	2
3	New drugs for HDL-C disorders: the beginning. *Current Medicinal Chemistry*, **2014**, 21, 2947-51	4.3	2
2	Controversies on HDL: should it be a target biomarker in patients with lipid disorders?. *Current Vascular Pharmacology*, **2014**, 12, 649-52	3.3	1
1	Lipidomics: Opportunities to Identify New Causal Mechanisms and Therapeutics for Atherosclerosis. *Current Cardiovascular Risk Reports*, **2013**, 7, 60-65	0.9	